Skip to main content

Treatment Clinical Trials for Acute Myeloid Leukemia (AML)

Review the acute myeloid leukemia (aml) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-200 of 305

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Quizartinib, Decitabine, and Venetoclax in Treating Patients with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
SNDX-5613 with Decitabine/Cedazuridine, and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, SAVE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Modified Memory-Like NK Cells and TCRαβ T-cell Depleted Half-Matched Related Donor Transplant for the Treatment of High-Risk Acute Myeloid Leukemia (ABCD NK trial)
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients with Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients with Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ONC201 Alone or in Combination with Venetoclax in Treating Patients with Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
PRAME-TCR-NK Cells with Lymphodepleting Chemotherapy for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (TGFBR2 KO CAR27/IL-15 NK cells) for the Treatment of Relapsed or Refractory Myeloid Malignancies
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
αβT Cell/CD19+ B Cell Depletion for Alternative Donor Stem Cell Transplant for Children and Young Adults with Hematologic Malignancies
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Chemotherapy (Decitabine in Combination with FLAG-Ida) and Total-Body Irradiation followed by Donor Stem Cell Transplant for the Treatment of Adults with Myeloid Malignancies at High Risk of Relapse
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
211^At-BC8-B10 before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
211At-BC8-B10 followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Venetoclax Combined with Intensive Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia or Intermediate and Higher Risk Myelodysplastic Syndrome
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
CPX-351 with Gemtuzumab Ozogamicin for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Decitabine Alone or in Combination with Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ziftomenib with Venetoclax and Gemtuzumab Ozogamicin for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia or Mixed Phenotype Acute Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas